Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041)

Cancer Chemotherapy and Pharmacology

Volumn 79, Issue 4, 2017, Pages 651-660

  Yamazaki, Naoya ^a   Takenouchi, Tatsuya ^b   Fujimoto, Manabu ^c   Ihn, Hironobu ^d   Uchi, Hiroshi ^e   Inozume, Takashi ^f   Kiyohara, Yoshio ^g   Uhara, Hisashi ^h   Nakagawa, Kazuhiko ⁱ   Furukawa, Hiroshi ^j   Wada, Hidefumi ^k   Noguchi, Kazuo ^l   Shimamoto, Takashi ^l   Yokota, Kenji ^m  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NIIGATA CANCER CENTER HOSPITAL   (Japan)

^c UNIVERSITY OF TSUKUBA   (Japan)

^d KUMAMOTO UNIVERSITY   (Japan)

^e KYUSHU UNIVERSITY   (Japan)

^f UNIVERSITY OF YAMANASHI   (Japan)

^g SHIZUOKA CANCER CENTER   (Japan)

^h SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^j HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^k YOKOHAMA CITY UNIVERSITY   (Japan)

^l Merck Sharp Dohm Res Labs Japan   (Japan)

^m NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

Anti PD 1 therapy; Immunotherapy; Japanese patients; Melanoma; Pembrolizumab

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; PEMBROLIZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BRAIN DISEASE; BRAIN HEMORRHAGE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHOLESTASIS; CLINICAL ARTICLE; COLITIS; CUTANEOUS MELANOMA; DIARRHEA; DRUG ERUPTION; DRUG SAFETY; DRY SKIN; EOSINOPHIL COUNT; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; HYPERTHYROIDISM; HYPOPHYSITIS; HYPOPIGMENTATION; HYPOTHYROIDISM; JAPANESE (PEOPLE); LYMPHOCYTOPENIA; MACULOPAPULAR RASH; MALAISE; MALE; MUCOSAL MELANOMA; MULTICENTER STUDY; NAUSEA; OPEN STUDY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER ABDOMINAL PAIN; VITILIGO; ANTAGONISTS AND INHIBITORS; ASIAN CONTINENTAL ANCESTRY GROUP; CLINICAL TRIAL; DISEASE FREE SURVIVAL; GENETICS; IMMUNOLOGY; MELANOMA; MIDDLE AGED; PATHOLOGY; SKIN; SKIN NEOPLASMS; SURVIVAL ANALYSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; PROGRAMMED CELL DEATH 1 RECEPTOR; SKIN; SKIN NEOPLASMS; SURVIVAL ANALYSIS;

EID: 85014741205     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-016-3237-x     Document Type: Article

References (29)

1. Kibbi N, Kluger H, Choi JN (2016) Melanoma: Clinical Presentations. Cancer Treat Res 167:107–129. doi:10.1007/978-3-319-22539-5_4
2. Spencer HL, Mehnert JM (2016) Mucosal Melanoma: Epidemiology, Biology and Treatment. Cancer Treat Res 167:295–320. doi:10.1007/978-3-319-22539-5_13
3. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11
4. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90
5. Ishihara K, Saida T, Otsuka F, Yamazaki N et al (2008) Statistical profiles of malignant melanoma and other skin cancers in Japan: 2007 update. Int J Clin Oncol 13:33–41
6. Chang JW, Yeh KY, Wang CH, Yang TS, Chiang HF, Wei FC et al (2004) Malignant melanoma in Taiwan: a prognostic study of 181 cases. Melanoma Res 14:537–541
7. Cress RD, Holly EA (1997) Incidence of cutaneous melanoma among non-Hispanic whites, Hispanics, Asians, and blacks: an analysis of California cancer registry data, 1988–93. Cancer Causes Control 8:246–252
8. Hao M, Zhao G, Du X, Yang Y, Yang J (2016) Clinical characteristics and prognostic indicators for metastatic melanoma: data from 446 patients in north China. Tumour Biol 37(8):10339–10348. doi:10.1007/s13277-016-4914-4 (Epub ahead of print)
9. Kuk D, Shoushtari AN, Barker CA, Panageas KS, Munhoz RR, Momtaz P et al (2016) Prognosis of mucosal, uveal, acral, nonacral cutaneous, and unknown primary melanoma from the time of first metastasis. Oncologist 21:848–854. doi:10.1634/theoncologist.2015-0522
10. Curtin JA, Busam K, Pinkel D, Bastian BC (2006) Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 24(26):4340–4346
11. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H et al (2005) Distinct sets of genetic alterations in melanoma. N Engl J Med 353:2135–2147
12. Handolias D, Salemi R, Murray W, Tan A, Liu W, Viros A et al (2010) Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure. Pigm Cell. Melanoma Res 23(2):210–215
13. Kong Y, Si L, Zhu Y, Xu X, Corless CL, Flaherty KT et al (2011) Large-scale analysis of KIT aberrations in Chinese patients with melanoma. Clin Cancer Res 17(7):1684–1691
14. Furney SJ, Turajlic S, Stamp G, Thomas JM, Hayes A, Strauss D et al (2014) The mutational burden of acral melanoma revealed by whole-genome sequencing and comparative analysis. Pigment Cell. Melanoma Res 27:835–838
15. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R et al (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 11:369(2):134–144
16. Patnaik A, Kang SP, Rasco D, Papadopoulos KP, Elassaiss-Schaap J, Beeram M et al (2105) Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. Clin Cancer Res 21:4286–4293
17. Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C et al (2015) Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 16:908–918
18. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L et al (2015) Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372:2521–2532
19. Robert C, Joshua AM, Weber JS, Ribas A, Hodi FS, Kefford RF et al (2014) Pembrolizumab (Pembro; MK-3475) for advanced melanoma (MEL): randomized comparison of two dosing schedules. Ann Oncol 25 (suppl 4). doi:10.1093/annonc/mdu438.42
20. Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R et al (2014) Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. The Lancet 384:1109–1117
21. Shimizu T, Seto T, Hirai F, Takenoyama M, Nosaki K, Tsurutani J et al (2016) Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors. Invest New Drugs 34(3):347–354
22. Friedman CF, Proverbs-Singh TA, Postow MA (2016) Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol. doi:10.1001/jamaoncol.2016.1051 (Epub ahead of print)
23. Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L et al (2016) Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival analysis of KEYNOTE-006 [Abstract]. J Clin Oncol 34(suppl; abstr 9504)
24. Shoushtari AN, Munhoz RR, Kuk D, Ott PA, Johnson DB, Tsai KK et al (2016) The efficacy of anti-PD-1 agents in acral and mucosal melanoma. Cancer. doi:10.1002/cncr.30259 (Epub ahead of print)
25. Algazi AP, Tsai KK, Shoushtari AN, Munhoz RR, Eroglu Z, Piulats JM et al (2016) Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. doi:10.1002/cncr.30258 (Epub ahead of print)
26. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD et al (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:23e34. doi:10.1056/NEJMoa1504030.
27. Long GV, Atkinson V, Cebon J, Jameson M, Fitzharris B, McNeil C et al (2016) Pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma: Results of the KEYNOTE-029 expansion cohort [Abstract]. J Clin Oncol 34(suppl; abstr 9506)
28. Long GV, Dummer R, Ribas A, Puzanov I, VanderWalde A, Hans R et al (2016) Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma [Abstract]. J Clin Oncol 34(suppl; abstr 9568)
29. Gangadhar TC, Hamid O, Smith DC, Bauer TM, Wasser JS, Luke JJ et al (2015) Preliminary results from a Phase I/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers. J Immuno Ther Cancer 3(Suppl 2):O7. doi:10.1186/2051-1426-3-S2-O7